Translation of the instructions can be
Darrow's solution solution for infusion
Instruction
For medical use of the medicinal product
Darrow solution
(Darrow's solution)
Composition:
Active ingredients: sodium chloride, potassium chloride, sodium lactate;
100 ml of solution contains: sodium chloride - 0.4 g; potassium chloride - 0.267 g; sodium lactate -0.594 g;
ionic composition per 1000 ml of solution: Na + - 121 mmol, K + - 36 mmol, Cl - - 104 mmol, lactate -53 mmol;
excipient: water for injections.
Dosage form.
Solution for infusion.
Main physicochemical properties: clear colorless liquid; theoretical osmolarity - 314 mosmol/l; pH 5.5-7.5.
Pharmacotherapeutic group.
Plasma replacement and perfusion solutions. solutions used to correct electrolyte imbalances. electrolytes.
PBX code B05B B01.
Pharmacological properties.
Pharmacodynamics.
Isoosmotic electrolyte solution with a high content of potassium and lactate. The latter is transformed into bicarbonate in the liver, which gives the solution alkaline properties. In the absence of violations of the functional state of the liver and with sufficient oxygen supply to the cells, lactate acts as an energy source.
Pharmacokinetics.
When administered intravenously, the components of the drug are rapidly excreted by the kidneys. Lactate is metabolized in the liver.
Clinical characteristics.
Indication.
Correction of water and electrolyte balance disorders in dehydration, accompanied by hypokalemia and acidosis; with prolonged administration of oral diuretics, accompanied by potassium loss; to restore water and electrolyte balance in preparing patients for surgery, in the intra- and postoperative period.
Contraindication.
Hypervolemia, hypernatremia (including due to the use of corticosteroids), hyperkalemia, hyperchloremia, acute and hypertensive dehydration, pulmonary edema, decompensated heart failure, eclampsia, severe cardiac and/or renal dysfunction, hepatic failure (due to reduced formation of bicarbonate from lactate), thrombophlebitis, conditions with increased blood clotting, decompensated heart defects.
Alkalosis, lactic acidosis, severe arterial hypertension, oliguria, anuria, cerebral edema, hypersensitivity to the components of the drug.
Special safety measures.
When large volumes are administered, when the serum potassium concentration reaches a high level (6.5-8 mmol/L), hyperkalemia with cardiac arrhythmia may occur.
Interaction with other drugs and other types of interactions.
The risk of developing hyperkalemia increases when using potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, and potassium supplements.
The drug is incompatible with cefamandole, amphotericin, ethyl alcohol, thiopental, aminocaproic acid, metaraminol, ampicillin, vibramycin and monocycline.
It is not recommended to use the drug as a means for diluting antibiotics administered by infusion, as well as for diluting anti-inflammatory drugs.
Sodium retention in the body may increase with the simultaneous use of the following drugs: nonsteroidal anti-inflammatory drugs, androgens, anabolic hormones, estrogens, corticotropin, mineralocorticoids, vasodilators or ganglioblockers.
Due to the presence of lactate, which alkalizes the pH, caution should be exercised when using the drug simultaneously with drugs whose renal elimination depends on pH. Renal clearance of salicylates, barbiturates, lithium may decrease, and sympathomimetics and stimulants (such as dexamfetamine sulfate, fenfluramine hydrochloride) may increase.
Application features.
Blood should be monitored for electrolyte content, changes in pH and pCO2 values, and water balance control.
Due to the content of sodium ions, the drug should be used with caution in elderly patients, patients with arterial hypertension, renal and cardiovascular failure, with congestive heart failure, especially in the postoperative period, as well as in patients with clinical conditions accompanied by sodium retention and edema, and patients with hypoxia.
"Darrow's solution", which contains sodium, should be used with caution in patients receiving corticosteroids or corticotropin.
The potassium content requires caution when using the solution in patients with heart disease and clinical conditions that are accompanied by potassium retention in the body.
When using potassium preparations, cardiac activity should be monitored using an ECG, especially in patients receiving cardiac glycosides.
In patients with reduced kidney function, the administration of Darrow Solution may lead to sodium or potassium retention in the body.
"Darrow's solution" is not used as a solvent for blood products.
The use of intravenous solutions can cause fluid and/or solute overload, hyperhydration, congestion, and pulmonary edema. The risk of dilution is inversely proportional to electrolyte concentration. The risk of solution overload, which causes congestion with peripheral edema and pulmonary edema, is directly proportional to electrolyte concentration.
If any signs of a hypersensitivity reaction appear, immediately discontinue the administration of the solution and provide the necessary treatment.
Since the drug contains sodium lactate, it should be used with extreme caution in patients prone to hypernatremia (for example, with adrenocortical insufficiency, diabetes insipidus, or massive tissue damage) or in patients with heart disease.
Use during pregnancy or breastfeeding.
The drug should be used during pregnancy only in cases where the expected benefit of treatment outweighs the possible risk to the fetus.
The ability to influence the reaction speed when driving vehicles or other mechanisms.
Data are missing due to the use of the drug exclusively in a hospital setting.
Method of administration and doses.
Administer intravenously by drip in a daily dose of 100 ml to 2 l. The dose is prescribed by the doctor depending on the patient's condition, the course of the disease, and indicators of the state of water and electrolyte balance.
The maximum rate of administration is 20-30 drops per minute.
The duration of treatment depends on the patient's condition and is determined by the doctor individually.
Children.
Do not use in pediatrics due to lack of clinical trials.
Overdose.
The introduction of a large volume of solution or too rapid administration may lead to cardiopulmonary decompensation, disruption of water and electrolyte balance (hypervolemia, hypernatremia, hyperkalemia, hyperchloremia) and / or acid-base balance (alkalosis). In this case, the administration of the drug should be stopped immediately. Conduct symptomatic therapy.
Adverse reactions.
Electrolyte imbalance: changes in serum electrolyte levels (hyperkalemia, hypernatremia, hyperchloremia); metabolic alkalosis; chloride acidosis.
General reactions of the body: hypervolemia; hyperhydration; allergic or anaphylactic reactions (increased body temperature, itching, cough, sneezing, difficulty breathing, localized or generalized urticaria, angioedema); panic attack; paresthesias; cardiac arrhythmias, increased number of extrasystoles.
Adverse reactions may occur at the site of injection of the solution: inflammation, swelling, rash, itching, erythema, pain, burning, numbness at the infusion site, thrombophlebitis.
Rapid administration of the drug may cause acute circulatory failure and pulmonary edema.
In case of adverse reactions, the administration of the solution should be stopped, the patient's condition should be assessed and appropriate assistance should be provided.
Expiration date.
5 years.
Storage conditions.
Store at a temperature not exceeding 25 °C out of the reach of children.
Incompatibility.
The solution should not be mixed with other drugs.
Packaging.
200 ml or 400 ml in bottles.
Vacation category.
According to the recipe.
Producer.
Private Joint Stock Company "Infusion".
Location of the manufacturer and address of its place of business.
Ukraine, 23219, Vinnytsia region, Vinnytsia district, Vinnytsia Khutora village, Nemyrivske Shosse str., 84a.
